Open AccessEFFECT OF ENDOSTATIN AND INSULIN-LIKE GROWTH FACTOR-1 ON ANGIOGENESIS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION WITH OBESITY UNDER THE INFLUENCE OF ZOFENOPRIL
Author(s) -
D. Martovytskyi,
Olexiy M Shelest,
Павло Григорович Кравчун
Publication year - 2020
Publication title -
wiadomości lekarskie
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.133
H-Index - 14
eISSN - 2719-342X
pISSN - 0043-5147
DOI - 10.36740/wlek202001111
Subject(s) - angiogenesis , endostatin , medicine , obesity , myocardial infarction , endocrinology , oncology , cardiology , cancer research
The aim: To study the dynamics of markers of angiogenesis based on insulin-like growth factor-1 (IGF-1) and endostatin, as well as to determine 6-month survival in patients taking zofenopril from the first day of AMI with and without obesity.Materials and methods: using enzyme immunoassay, we determined the level of endostatin and IGF-1 in serum on days 1 and 12 in patients with AMI with the presence and absence of obesity, and a statistical processing of the data obtained.Results: The relationship between obesity and angiogenesis indicators, both activators and inhibitors, was determined, and a significant relationship was found between zofenopril therapy and angiogenesis activator IGF-1. Differences in the survival of patients with complicated AMI were determined depending on the choice of ACE inhibitor in favor of a higher survival rate of patients who took zofenopril.Conclusions: patients who underwent complicated AMI, taking zofenopril, have a higher survival rate during the 6-month follow-up period. Zofenopril stimulated angiogenesis in the examined patients, which was expressed in patients with and without obesity.